- Poster presentation
- Open access
- Published:
Oral melatonin in high-risk critically ill patients: quality of sedative effect
Critical Care volume 16, Article number: P322 (2012)
Introduction
Analgesic/sedative therapy is necessary in ICU patients; however, it presents important side effects. Critically ill patients have altered circadian rhythm, delirium and agitation often requiring additional sedation. The dramatically reduced endogenous blood melatonin level (basal and night peaks) could play a role in this context. We evaluated the effects of oral melatonin administration on the adaptation to critical illness and invasive procedures in high-risk critically ill patients [1] consciously sedated [2].
Methods
Double-blind RCT between placebo and melatonin (3 mg bid, 8:00 and 12:00 p.m., from third ICU day until discharge). Inclusion: age >18, SAPS II >32, expected mechanical ventilation (MV) >4 days, practicability of the gastroenteric tract. Patients were treated according to local guidelines [2], titrating sedatives to a conscious target (Richmond Agitation Sedation Scale (RASS) = 0) as early as possible. Each day, the physician in charge stated the RASS target; nurses assessed the actual RASS.
Results
Eighty-two patients enrolled: age 72 (60 to 77), SAPS II 41 (34 to 54), MV length 11 (6 to 22) days. Fifteen pancreatitis, 33 acute lung diseases, 13 acute heart diseases, 21 other. The analgesic/sedative therapy during the first 3 days was not different between groups. Melatonin administration determined early weaning from sedatives and analgesics. The prevalence of conscious sedation (RASS = 0) was higher in the melatonin group (67.9 vs. 60.1%, P < 0.01), while deeper levels of sedation (RASS = -3/-4) were lower in the melatonin group (RASS -3: 2.4 vs. 7.7%, P < 0.01; RASS -4: 1.9 vs. 4.3%, P < 0.01). Melatonin administration caused no oversedation (26.3 vs. 24.2%, P = 0.94), while decreased undersedation (18.6% vs. 26.2%, P = 0.05). RASS targets were joined more frequently in the melatonin group, even if not significantly (55.1 vs. 49.6%, P = 0.12).
Conclusion
Oral melatonin increased the prevalence of conscious sedation in high-risk critically ill patients; it allowed a better achievement of RASS target, particularly decreasing undersedation episodes.
Clinicaltrial.gov NCT00470821
References
Iapichino , et al.: Crit Care Med. 2006, 34: 1039. 10.1097/01.CCM.0000206286.19444.40
Cigada , et al.: J Crit Care. 2008, 23: 349. 10.1016/j.jcrc.2007.04.003
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Sabbatini, G., Mistraletti, G., Cerri, B. et al. Oral melatonin in high-risk critically ill patients: quality of sedative effect. Crit Care 16 (Suppl 1), P322 (2012). https://doi.org/10.1186/cc10929
Published:
DOI: https://doi.org/10.1186/cc10929